compound introduction
AM-1638 is a potent and orally bioavailable GPR40/FFA1 full agonist with an EC 50 of 0.16 μM. In Vivo AM-1638 exhibits moderate cross-species plasma clearance and volume of distribution, resulting in plasma half-lives suitable for evaluation of its antidiabetic properties in mouse, rat, and cynomologus monkey. Moreover, oral administration of full agonist AM-1638 demonstrates excellent oral bioavailability (mouse, >100%; rat, 72%; and cyno, 71%). AM-1638 exhibits antidiabetic activity in BDF/DIO mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid IC50& Target:IC50: 0.16 μM (GPR40/FFA1)
